BioFluidica is an early stage diagnostics company now launching it's multi-omics, liquid biopsy LiquidScan platform for the isolation of multiple types of biomarkers (cells, exosomes and cell free DNA) from blood for oncology, infectious diseases and prenatal diagnostics. Our first LDT, Cell-Based Prenatal DNA Testing, will arrive end of 2024 for aneuploidies and single gene disorder testing.